




**ANNUAL MEETING**  
Fontainebleau Miami Beach  
Miami, Florida . February 9-11

## PROGRAM SPEAKERS



***Deborah Autor, J.D.***

***Senior Vice President, Strategic Global Quality & Regulatory Policy, Mylan, Inc.***

Deborah M. Autor is Senior Vice President, Strategic Global Quality and Regulatory Policy at Mylan, the world's third largest generics and specialty pharmaceutical company. In that role, Ms. Autor runs Global Quality for Mylan. She works to advance Mylan's efforts to ensure high drug quality standards globally and to expand the world's access to high quality medicine.

Prior to joining Mylan in 2013, Ms. Autor served for almost 12 years at the U.S. FDA, most recently as Deputy Commissioner for Global Regulatory Operations and Policy. In that role, Ms.

Autor supervised the 4,400 employees in FDA's field force and international offices. Before that, Ms. Autor served as Director of the Office of Compliance of the Center for Drug Evaluation and Research where she led key programs for drugs including: current good manufacturing practices; human subject protection and bioresearch monitoring; marketed unapproved drugs; and pharmaceutical import and export.

Before joining FDA, Ms. Autor was a trial attorney for seven years in the Office of Consumer Litigation of the U.S. Department of Justice, where she litigated civil and criminal FDA-related cases.

Ms. Autor was awarded the 2011 Meritorious Executive Presidential Rank Award, the 2011 Food and Drug Law Institute's Distinguished Service and Leadership Award. She was also was a 2010 finalist for the prestigious Service to America Medal. In 2014, Ms. Autor was elected to the Board of Directors of the Parenteral Drug Association, the leading global provider of science, technology, and regulatory information and education for the pharmaceutical and biopharmaceutical community, consisting of more than 9,500 members worldwide.



***Elaine Herrmann Blais, J.D.***

***Partner, Goodwin Procter LLP***

Elaine Herrmann Blais is a partner in Goodwin Procter's IP Litigation Group. For nearly two decades, Ms. Blais has focused her practice on intellectual property litigation, particularly on patent litigation. Ms. Blais has handled numerous patent infringement lawsuits in federal courts nationwide. She has advised clients on and participated in all phases of patent litigation, from initial counseling through trial and appeal. Ms. Blais has worked on patent cases involving diverse areas of technology and has significant experience in Hatch-Waxman litigation. Ms.

Blais has also represented members of GPhA on legislative matters, including matters relating to the America Invents Act and the Biologics Price Competition and Innovation Act. She is a lead author of Goodwin Procter's recent publication entitled "Biosimilars: A Guide to Regulatory and Intellectual Property Issues."



***Ronny Gal, Ph.D.***

***Senior Analyst, Sanford C. Bernstein & Co.***

Aaron (Ronny) Gal is the Senior Research Analyst covering the specialty pharmaceutical industry at Sanford C. Bernstein, providing research and investment insights on specialty and generic pharmaceutical stocks to institutional clients around the world. His work is recognized in third-party surveys, including those conducted by Institutional Investor and Greenwich Associates. Prior to joining Bernstein, Mr. Gal spearheaded Canon's business development in life sciences. He also spent six years with the Boston Consulting Group, advising clients in the pharmaceutical and healthcare delivery sectors. Mr. Gal was awarded a PhD from the Massachusetts Institute of Technology and holds a BSc from Emory University.



***Christopher T. Holding, J.D.***

***Partner, Goodwin Procter LLP***

Christopher T. Holding is a Litigation Partner with Goodwin Procter LLP and chair of the firm's Antitrust & Competition Practice. Mr. Holding has particular expertise in issues involving the intersection of antitrust and intellectual property, and his practice involving pharmaceuticals is at the forefront of competition issues in the industry. His experience includes defending clients in governmental investigations and private class actions challenging "reverse payment" settlement agreements, representing the plaintiff in the first "product hopping" case to go to trial, representing clients in cases involving allegations of fraudulent patent procurement and sham litigation, litigating intellectual property damages issues in connection with "at risk" launches of generic products, and advising clients on competition issues in relation to Risk Evaluation and Mitigation Strategies ("REMS") programs.



***Doug Long***

***Vice President, Industry Relations, IMS Health, Inc.***

Doug Long is Vice President of Industry Relations at IMS Health, the world's largest pharmaceutical information company. Mr. Long, who has been with IMS Health since 1989, focuses on securing data for all existing and new databases supported by IMS Health, managing supplier, manufacturer and association relationships, and developing information for data partners. He has considerable experience with, and unique perspective on, the changing U.S. and global health care marketplace and pharmaceutical distribution.



***James E. Malackowski, J.D.***

***Chairman and CEO, Ocean Tomo, LLC.***

James E. Malackowski is the Chairman and Chief Executive Officer of Ocean Tomo, LLC, the Intellectual Capital Merchant Banc™ firm providing industry leading financial products and services related to intellectual property including financial expert testimony, valuation, strategy consulting, proprietary research products, investment services, risk management products, innovation management services and transaction brokerage.

Mr. Malackowski has been recognized annually since 2007 by leading industry publications as one of the 'World's Leading IP Strategists'. Significantly, Mr. Malackowski is listed among "50 Under 45" by IP Law & Business™; included in the National Law Journal's inaugural list of 50 Intellectual Property Trailblazers & Pioneers; and, named as one of "The Most Influential People in IP" by Managing Intellectual Property™.

As an inventor, Mr. Malackowski has more than twenty issued U.S. patents. He is a frequent instructor for graduate studies on IP management and markets and a Summa Cum Laude graduate of the University of Notre Dame, majoring in accountancy and philosophy. Mr. Malackowski is Certified in Financial Forensics, a Certified Licensing Professional and a Registered Certified Public Accountant in the State of Illinois.



**Rajiv Malik**  
**President, Mylan, Inc.**


Rajiv Malik is Mylan's president, and is responsible for the company's operations. He also serves on Mylan's board of directors. Malik's responsibilities as president include overseeing research and development (R&D), business development, regulatory affairs, manufacturing, quality, supply chain, and medical affairs, as well as the sales and marketing of Mylan's generics business. He also is responsible for helping lead Mylan's expansion into emerging and other new commercial markets, such as the company's commercial launch in India in 2012. Malik has held important leadership positions at Mylan since January 2007, when the company acquired a controlling stake in Matrix Laboratories Limited (now Mylan Laboratories Limited), one of the world's largest suppliers of active pharmaceutical ingredients. At the time of the acquisition, Malik was Matrix's chief executive officer. Among his earlier contributions at Mylan, Malik played a key role in significantly expanding and diversifying the company's global product portfolio, pipeline and manufacturing footprint. In partnership with Mylan's leadership team, he played a significant role in leading the integrations of Mylan and Matrix and Mylan and the generics business of Merck KGaA to leverage the benefits of global scale and vertical and horizontal integration. He also helped establish Mylan as a leader in antiretroviral medicines, particularly in developing markets. Malik has approximately 30 years of experience in the global generic pharmaceutical industry. Prior to joining Matrix in 2005, Malik was head of Global Development and Regulatory at Sandoz. He started his R&D career at Ranbaxy Laboratories, rising to head of Generics R&D. Malik earned his master's degree in pharmaceutical technology from Punjab University, India, and has more than 60 process patents to his credit.



**Bill McIntuff**  
**Partner and Co-founder, Public Opinion Strategies**

Bill McIntuff is a partner and co-founder of Public Opinion Strategies, a national political and public affairs survey research firm. Called by The New York Times, "the leading Republican polling company," Public Opinion Strategies currently represents 15 U.S. Senators, six governors, and over 75 Members of Congress. Bill is actively engaged in American politics, conducting national survey research on behalf of the Republican Governors Association. The focus of much of Bill's work has been health care, having completed more than 500 focus groups and more than 200 national surveys on this topic alone.

Bill, along with Peter Hart of Peter D. Hart Research Associates also conducts The NBC News/*The Wall Street Journal* Poll. He has appeared on *Meet the Press*, *Face the Nation*, and is frequently quoted in a variety of national news magazines and major newspapers.



**Mark Mellman**  
**President & CEO, The Mellman Group**

Mark Mellman is one of the nation's leading public opinion researchers and communication strategists. As CEO of The Mellman Group, a polling and consulting firm whose clients include leading political figures, Fortune 500 companies, and some of the nation's most important public interest groups, Mellman has helped guide the campaigns of 26 U.S. Senators, 10 Governors, over two dozen Members of Congress, and numerous state and local officials. The Mellman Group was recently awarded the prestigious "Pollster of the Year" award from the American Association of Political Consultants, the Group's third win.

Mellman has served as a consultant to CBS News, and as a presidential debate analyst for PBS and The Wall Street Journal. His op-eds have appeared in The New York Times, Washington Post, The Los Angeles Times and The Wall Street Journal among others, and he writes an influential weekly column for The Hill.



**Marty Murawski**  
**Vice President, Quality Systems, Hospira, Inc.**

Marty Murawski is currently the Vice President of Quality Systems at Hospira since May 2012. In this role, Marty is responsible for the oversight of the Global Complaint System, Supplier Quality, Document/Label Control, CAPA system, Compliance, Field Actions, Training, QA IT and Management Controls. Prior to joining Hospira, Marty was Director Regional Quality Services for the US/Puerto Rico/Ireland Region in Global Pharmaceutical Operations at Abbott. Marty began his career at Abbott Laboratories after graduating from the University of Wisconsin-Whitewater with a B.S.



**Ralph G. Neas**

***President & CEO, Generic Pharmaceutical Association***

Ralph G. Neas is the President and CEO of the Generic Pharmaceutical Association (GPhA). Prior to joining GPhA, he was the President and CEO of the National Coalition on Health Care (NCHC), a nonpartisan centrist coalition of more than eighty national organizations. For more than 30 years, Neas focused principally on civil rights, civil liberties, health and consumer issues, serving as the Executive Director of the nonpartisan Leadership Conference on Civil Rights (the nation's oldest and largest coalition), as President and CEO of the nonpartisan People For the American Way, and as a chief counsel in the U.S. Senate, first to Senator Edward W. Brooke (R-MA) and then to Senator Dave Durenberger (R-MN). Neas earned his B.A. from the University of Notre Dame and his J.D. from the University of Chicago Law School. Neas has also taught at the University of Chicago Law School, Georgetown University Law Center, and Harvard's Kennedy School of Government.



**Joseph C. Papa**

***President, Chief Executive Officer and Chairman, Perrigo Company plc***


Mr. Papa joined Perrigo in October 2006 as President and Chief Executive Officer. He was elected as a director in November 2006 and, subsequently, was appointed as Chairman of the Board of Directors in October 2007. Previously, Mr. Papa served as Chairman and Chief Executive Officer of the Pharmaceutical and Technologies Services segment of Cardinal Health, Inc., as President and Chief Operating Officer of Watson Pharmaceuticals, Inc., and in management positions at DuPont Pharmaceuticals, Pharmacia Corporation, G.D. Searle & Company and Novartis AG. Mr. Papa currently serves as a director of Smith & Nephew.



**Sigurdur (Sigg) Olafsson**

***President and Chief Executive Officer, Global Generic Medicines Group  
Teva Pharmaceuticals***

Sigg Olafsson joined Teva as President and Chief Executive Officer, Global Generic Medicines Group in 2014. Mr. Olafsson served as President of Actavis Pharma from 2012 to 2014, Executive Vice President, Global Generics at Actavis plc (Watson) from 2010 to 2012 and CEO of the Actavis Group from 2008 to 2010. From 2003 to 2008, he held positions of increasing responsibility within the Actavis Group, including Deputy CEO, Vice President of Corporate Development and CEO of Actavis Inc. U.S. From 1998 to 2003, he held positions of increasing responsibility with Pfizer's Global R&D organization in the U.K. and U.S. From 1994 to 1998, he served as Head of Drug Development for Omega Farma in Iceland. Mr. Olafsson received a M.S. in pharmacy (Cand Pharm) from the University of Iceland, Reykjavik.



**Randall Stanicky**

***Managing Director, Equity Research, RBC Capital Markets***

Randall is currently Managing Director, RBC Capital Markets and lead analyst of the specialty and generic pharmaceuticals research team in New York. He has more than 15 years of experience covering several healthcare sectors on both the buy and sell-side, most recently at Canaccord Genuity and Goldman Sachs. Prior to becoming a sell-side analyst, Randall followed healthcare stocks on the buy side at Citigroup Global Asset Management. He has been recognized by several external surveys, including Institutional Investor and StarMine, among others. He is a regular Wall Street speaker at international conferences and is a regular contributor to mainstream print, radio and TV media, presenting his views on the industry. Randall received a bachelor's degree in commerce from the University of British Columbia and he is a CFA charterholder. Randall is also a Board Member of TherapeuticsMD and Children's Tumor Foundation.




**Brian Rubenstein, J.D.**  
**Executive Counsel, Teva Pharmaceuticals**

Brian Rubenstein is Executive Counsel for Teva Pharmaceuticals USA, Inc. For over nine years he has managed and exercised direct oversight of Teva's portfolio of product liability, patent settlement antitrust and other commercial matters. Mr. Rubenstein guides and counsels Teva through all stages of litigation and dispute resolution both in federal court and in numerous state court jurisdictions. Most prominently, Mr. Rubenstein managed Teva's involvement in the landmark US Supreme Court case, *Pliva v. Mensing*, which memorialized a sea change in the law concerning generic pre-emption. Mr. Rubenstein also counsels the Company on antitrust, labeling and related regulatory issues. He received a Bachelor of Science degree from the Wharton School of Business at the University of Pennsylvania and a Juris Doctorate from Loyola University Chicago School of Law, where he graduated cum laude and was a member of the Law Review. Prior to joining Teva, Mr. Rubenstein litigated business disputes, including advertising and intellectual property disputes, at a large New York law firm.



**Kathleen Uhl, M.D.**  
**Director, Office of Generic Drugs, Food and Drug Administration**

Kathleen Uhl, MD currently serves as the Director for the Office of Generic Drugs in the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA). This office is responsible for the review and approval of Abbreviated New Drug Applications (ANDAs) and is largely tasked with implementing the Generic Drug User Fee Amendments (GDUFA). Dr. Uhl began her career with FDA in 1998 as a medical officer in the Office of Clinical Pharmacology and has served in numerous positions at FDA, including five years as the Assistant Commissioner for Women's Health and the Director of FDA's Office of Women's Health and, most recently, as the Deputy Director of the Office of Medical Policy in the CDER. She received her undergraduate degree from Temple University and her medical degree from the Medical College of Pennsylvania, with subsequent fellowship training in medical research and clinical pharmacology at the Uniformed Services University. She retains faculty appointments as Professor in Family Medicine and Internal Medicine at the Uniformed Services University and is a retired officer of the U.S. Public Health Service Commissioned Corps.



**Jeff Watson**  
**President, Apotex Corp., North America**

Jeff currently holds the position of President, US and Canada Commercial (Apotex Corp./Aveva/Apotex Inc.). He is responsible for all Canadian Commercial and U.S. operations within the Apotex Group of companies, reporting to the CEO. Jeff joined Apotex, the largest Canadian-owned pharmaceutical company, in 1993. Over the last 20 years, he has held various progressive positions within the Sales and Marketing Division, including time spent working in the retail pharmacy sector.

Jeff has been a member of the US Generic Pharmaceutical Association's (GPhA) Board of Directors since 2012. In 2008, he became an Executive Member of the Canadian Generic Pharmaceutical Association's (CGPA) board. He has served as CGPA's Vice Chairman since 2012. From 2004-2010 he served on the board for the Canadian Sports Hall of Fame (CSHOF). In 2009, Jeff was appointed to the board of the US Healthcare Distribution Management Association's knowledge partner, the Center for Healthcare Supply Chain Research. In 2011, he was named Vice Chair, and in 2012 he assumed the role of Chair. He is also on the Board of Directors for TruLeaf Sustainable Agriculture, Nova Scotia, Canada, and was recently named its Chair.



**Craig Wheeler**  
**President and CEO, Momenta Pharmaceuticals Inc.**

Craig A. Wheeler joined Momenta Pharmaceuticals, Inc. as Chief Executive Officer in September 2006. Momenta is a biotechnology company specializing in the detailed structural and functional analysis of complex drugs. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications. Mr. Wheeler also serves as a member of the Company's board of directors.



***Janet Woodcock, M.D.***

***Director, Center for Drug Evaluation and Research, U.S. Food and Drug Administration***

Janet Woodcock is Director of the Center for Drug Evaluation and Research (CDER), at the Food and Drug Administration (FDA). Dr. Woodcock first joined CDER in 1994. For three years, from 2005 until 2008, she served FDA's Commissioner, holding several positions, including as Deputy Commissioner and Chief Medical Officer, Deputy Commissioner for Operations, and Chief Operating Officer. Her responsibilities involved oversight of various aspects of scientific and medical regulatory operations. Before joining CDER, Dr. Woodcock served as Director, Office of Therapeutics Research and Review, and Acting Deputy Director in FDA's Center for Biologics Evaluation and Research. Dr. Woodcock received her M.D. from Northwestern Medical School and completed further training and held teaching appointments at the Pennsylvania State University and the University of California in San Francisco. She joined FDA in 1986.



***Frances (Fran) M. Zipp***

***President, Lachman Consultants***

Frances (Fran) M. Zipp is President of Lachman Consultant Services, Inc. Lachman Consultants provides compliance, regulatory and technical consulting services to the pharmaceutical and related industries. Ms. Zipp has a wealth of innovator and generic pharmaceutical industry operational and management experience. Formerly she was Group Executive Vice President and Global Head of Quality for Teva Pharmaceuticals, Senior Vice President of Quality at Wyeth Pharmaceuticals, Senior Vice President of Quality at Barr Pharmaceuticals, Head of U.S. Quality of Novartis (Ciba) and Chief Operating Officer at AAPI Pharma Sciences Corp. Ms. Zipp has been active in the pharmaceutical industrial and regulatory environment in the areas of quality metrics and drug shortages.